Regenicin, Inc.: 10-Q filed 2023-05-15
What Regenicin, Inc. reported in its quarterly report filed 2023-05-15 (fiscal Q1 2023): 21 published measures, 65 facts as tagged in accession 0001662252-23-000017.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-05-15
- Fiscal period
- fiscal Q1 2023
- Accession
- 0001662252-23-000017 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Regenicin, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 11,859,194 | USD | |
| At 2022-09-30 | 15,493 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | -6,211,939 | USD | |
| At 2022-12-31 | -5,934,425 | USD | |
| At 2022-09-30 | -5,597,140 | USD | |
| At 2022-03-31 | -5,278,652 | USD | |
| At 2021-12-31 | -5,112,003 | USD | |
| At 2021-09-30 | -4,957,878 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -336,435 | USD | 90 |
| 2022-10-01 to 2023-03-31 | -613,949 | USD | 182 |
| 2022-10-01 to 2022-12-31 | -277,514 | USD | 92 |
| 2022-01-01 to 2022-03-31 | -166,649 | USD | 90 |
| 2021-10-01 to 2022-03-31 | -320,774 | USD | 182 |
| 2021-10-01 to 2021-12-31 | -154,125 | USD | 92 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | -690,074 | USD | 182 |
| 2021-10-01 to 2022-03-31 | -17,146 | USD | 182 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-10-01 to 2023-03-31 | -978,010 | USD | 182 |
| 2021-10-01 to 2022-03-31 | 17,000 | USD | 182 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 16,573,799 | USD | |
| At 2022-09-30 | 15,959,850 | USD |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 153,483,050 | shares | 90 |
| 2022-10-01 to 2023-03-31 | 153,483,050 | shares | 182 |
| 2022-01-01 to 2022-03-31 | 153,483,050 | shares | 90 |
| 2021-10-01 to 2022-03-31 | 153,483,050 | shares | 182 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 0 | USD/shares | 90 |
| 2022-10-01 to 2023-03-31 | 0 | USD/shares | 182 |
| 2022-01-01 to 2022-03-31 | 0 | USD/shares | 90 |
| 2021-10-01 to 2022-03-31 | 0 | USD/shares | 182 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 0 | USD/shares | 90 |
| 2022-10-01 to 2023-03-31 | 0 | USD/shares | 182 |
| 2022-01-01 to 2022-03-31 | 0 | USD/shares | 90 |
| 2021-10-01 to 2022-03-31 | 0 | USD/shares | 182 |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 9,249 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 18,644 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 9,011 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 17,954 | USD | 182 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 18,070,283 | USD | |
| At 2022-09-30 | 5,612,633 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 103,119 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 327,836 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 595,455 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 155,513 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 302,045 | USD | 182 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 94,743 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 432,256 | USD | 182 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 153,483,050 | shares | |
| At 2022-09-30 | 153,483,050 | shares |
Cash including restricted cash
Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 10,880,109 | USD | |
| At 2022-09-30 | 14,568 | USD | |
| At 2022-03-31 | 1,713 | USD | |
| At 2021-09-30 | 1,859 | USD |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 10,208,339 | USD | |
| At 2022-09-30 | 10,208,339 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | -6,211,089 | USD | |
| At 2022-09-30 | -5,597,140 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 281,739 | USD | |
| At 2022-09-30 | 254,595 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -353,893 | USD | 90 |
| 2022-10-01 to 2023-03-31 | -649,252 | USD | 182 |
| 2022-01-01 to 2022-03-31 | -184,107 | USD | 90 |
| 2021-10-01 to 2022-03-31 | -356,077 | USD | 182 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 233,093 | USD | 90 |
| 2022-10-01 to 2023-03-31 | 163,199 | USD | 182 |
| 2022-01-01 to 2022-03-31 | 155,513 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 302,045 | USD | 182 |
Inspect the source
- Entity
- Regenicin, Inc. / CIK 0001412659
- Captured
- SEC response SHA-256
66d33e554adc1e643294d5e778c52aa5121a74d07c71bf640453c952267c0d14
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001412659.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))